An important goal of CCPM is to host a convening mechanism for identifying, vetting, prioritizing, and refining translational and clinical projects that provide outstanding opportunities for Dana-Farber/BWH/Broad investigators to make pivotal advances
in the precision medicine arena. Such projects may include (but are not limited to) the following categories:
- Using state-of-the-art and emerging technologies to identify cancer patients that benefit from new cancer drugs including conventional chemotherapy, targeted therapies, and immunotherapy
- Determining which targeted drugs are achieving their desired effects inside the tumor cells
- Defining the mechanisms by which cancers exhibit or develop resistance to therapies
- Developing proof-of-concept, hypothesis-driven clinical studies of different therapeutics and combinations in conjunction with investigators from disease centers with appropriate correlative studies
- Studying primary tumors and metastases to identify those patients whose tumors are likely to recur